Indian Hospital Sector: Why its Finally Starting to Look Interesting

Hospital stocks have tested investor patience for years. Capital went in early, returns arrived late, and valuations often assumed perfection long before execution showed up.

That history explains the caution many investors still carry. That long gap between capital deployment and returns is precisely why the sector still attracts scepticism today, even as numbers begin to improve.

The evidence behind this positive development is interesting. Recent quarterly numbers (Q2 FY26) suggest execution is starting to match expectations across several listed players.

This does not make hospitals a one-way bet, but it does make the sector worth revisiting with fresh eyes, especially after a decent price correction in most of them.

The Sector Backdrop: Why the Numbers are Improving

The hospital sector's long-term case rests on basic business arithmetic.

India has roughly 1.3-1.5 hospital beds per 1,000 people, compared with 4-5 beds per 1,000 in developed markets.

Even after adjusting for demographics and income levels, the supply gap remains large. Importantly, this gap cannot be closed quickly due to high capital costs, regulatory approvals, and talent constraints.

Private hospitals now account for 60-65% of inpatient care in India, a share that has steadily increased as healthcare delivery shifts toward organised, multi-specialty players.

Insurance penetration has crossed 40% of the population, up sharply from a decade ago. This reduces volatility in demand and improves affordability for higher-value procedures, which directly supports occupancy stability.

In recent times, case mix is also changing. Oncology, cardiac, orthopaedics, and neuro procedures are growing in the mid-teens annually, faster than general admissions.

Most large listed hospital groups completed heavy capex between FY18 and FY23. Bed additions as a percentage of existing capacity are now moderating.

The focus is shifting from building hospitals to making more revenue existing assets, which is typically when margins, ROE, and cash flows begin to respond positively.

Here are the important points investors need to consider...

1. Pricing is not the key driver of growth. Volumes are picking up

Historically, hospital growth often relied on pricing increases or one-off post-capex spikes, both of which faded quickly. The current phase looks more durable.

The Q2 FY26 earnings reports show the following:

• Fortis Healthcare: 20% YoY revenue growth, occupancy recovering to 70% from its 60% lows.

• Max Healthcare: 18% YoY, driven by stronger metro hospital utilisation.

• Narayana Hrudayalaya: 22% YoY on higher patient volumes and better case mix.

• Jupiter Lifeline: 17% YoY as new beds began contributing.

• Yatharth Hospital: 25% YoY from tier-2 expansion.

Volume-led growth with sustained occupancy usually delivers far better earnings visibility than pricing-led spikes.

2. Operating Leverage is Finally Showing Up

Hospitals are fixed-cost businesses where utilisation gains should translate into operating leverage. For years, this was promised more than it was delivered but things are now changing.

• Max Healthcare: EBITDA grew 25% versus 18% revenue growth

• Fortis Healthcare: Margins expanded to 24% from 20%, EV/EBITDA 35x

• Apollo Hospitals: 30x EV/EBITDA, supported by pharmacy and diagnostics

• Rainbow Children's: 25x EV/EBITDA with an asset-light model

• Narayana Hrudayalaya: 27x EV/EBITDA, leverage driven by rising volumes

This phase often marks the move from recovery to scalable earnings, though doctor costs, case mix, and regional competition remain key variables.

3. Return Ratios Are Moving After Years of Stagnation

ROE matters because it shows whether capital is finally being used well. After years of muted returns, the direction of change matters as much as the absolute number.

ROE levels (TTM, Q2 FY26):

• Indraprastha Medical (Apollo Delhi): 30%

• Narayana Hrudayalaya: 24%, well above the sector average of 12%

• Apollo Hospitals: 18%

• Max Healthcare: 12-13%, trending upward

• Fortis Healthcare: 10-11%, improving steadily

Rising ROE usually signals better capital discipline before peak profitability becomes obvious.

4. Cash Flows Are Becoming More Reliable

Cash conversion has historically been a weak spot for hospital businesses due to working capital needs and expansion cycles. Recent improvement is worth noting.

Cash flow from operations (CFO) to EBITDA conversion (Q2 FY26):

• Fortis Healthcare: 73%, aided by working capital cleanup

• Max Healthcare: 64%

• Narayana Hrudayalaya: 65%

• Apollo Hospitals: 60%+

• Healthcare Global Enterprises: 70%+

Better cash conversion strengthens balance sheets and reduces dilution risk during growth phases. It separates accounting profits from usable capital, which is critical for smooth financials.

5. Valuations: Less Euphoria, More Discrimination

The sector has corrected 20-30% from 2024 peaks, driven more by a sentiment change than earnings disappointment.

• Apollo Hospitals 60 PE (earlier 75)

• Max Healthcare 74 PE (earlier 90)

• Rainbow Children’s 53 PE

• Narayana Hrudayalaya 45 PE with 27 EV/EBITDA and 24% ROE

• Fortis Healthcare 55 PE with debt down 15% YoY and strong cash conversion

Historically, hospital stocks look expensive just before execution improves and appear cheap only after returns are already visible. Valuation comfort in this sector usually follows operational proof.

Valuation & Execution Snapshot: Key Hospital Players

Figures indicative and rounded for comparison.

How to Read This Table: This is not about finding the lowest multiple, but to understand valuations in a more holistic way.

• Narayana stands out on ROE-to-valuation comfort

• Apollo earns a premium through scale and diversification

• Fortis shows cash strength in a turnaround phase

• Max carries utilisation risk at higher multiples

• Smaller names demand quarterly discipline over narratives

6. Smaller Players: Faster Growth, Higher Variability

• Yatharth Hospital: Rapid expansion, leverage needs monitoring

• Artemis Medicare: Profitability turning positive

• Dr Agarwal’s Eye Care: Strong revenue momentum, elevated valuations

• Jupiter Lifeline: Execution consistency and cash generation remain key

Here, outcomes are decided quarter by quarter, not by long-term promise.

Three Ways the Sector Makes Money

• Narayana Hrudayalaya: Volume-led growth with high ROE

• Apollo Hospitals: Scale with diversified revenue streams

• Fortis Healthcare: Turnaround driven by improving cash flows

Different models, different paths, same requirement: execution.

Sector Outlook: What the Next Few Years Are Likely Look Like

Healthcare spending in India is expected to grow at 10-12% CAGR. For well-run hospital operators, revenue growth can remain in the high-teens, while EBITDA growth may outpace revenue as operating leverage improves.

Key drivers to watch:

• Insurance penetration

• Complex procedure mix

• Tier-2 and tier-3 expansion

• Capital discipline over aggressive capex

Execution, not expansion, will determine which company compounds better from here on.

Risks That Still Matter

• Regulatory pressure on pricing

• Rising doctor and talent costs

• Large capex cycles impacting short-term cash flowspressure on pricing

• Rising doctor and talent costs

• Large capex cycles impacting short-term cash flows

Strong quarters do not remove these risks and they need continuous tracking.

Closing Thoughts

Hospitals are not suddenly cheap or risk-free, but are more reasonably priced that before.

What is changing is execution quality which makes them interesting. Growth is becoming volume-driven, cash flows are improving, and return ratios are responding.

Interesting times ahead for this critical sector of Indian economy.

{TAGAG~EVERGREEN}